Yale Ovarian Cancer Detection Technology Licensed in China by SurExam

Jon Soderstrom and Jiasen Xu, CEO of SurExam ink the licensing agreement for commercialization of the technology for EOC detection developed by Gil Mor (upper left), while Carolyn Slayman, Deputy Dean of Yale Medical School and Zhinan Yin observe. [Photo by J. Damian/Yale] Yale University Office of Cooperative Research today announced that it has granted an exclusive license agreement with the Chinese company SurExam Life Science & Technology (Shenzhen) Co. for the commercialization of the university’s blood testing technology for epithelial ovarian cancer (EOC).